

## **I. AMENDMENT**

### **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

Claims 1-9. (canceled)

Claim 10. (currently amended) A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin or to a biologically active contortrostatin variant so that contortrostatin or said contortrostatin variant binds to the integrin, wherein said contortrostatin variant comprises an amino acid sequence at least 90% identical to amino acid numbers 419 to 483 of SEQ ID NO: 2 as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

Claim 11. (canceled) ~~A method of inhibiting the adhesion of integrin expressing cells to vitronectin comprising exposing said cells to contortrostatin so that contortrostatin binds to the integrin.~~

Claim 12. (withdrawn) A homodimeric disintegrin comprising an amino acid sequence which is at least 90% percent identical to amino acid numbers 419 to 483 of SEQ ID NO: 2, wherein said contortrostatin amino acid sequence (i) binds to integrin  $\alpha v \beta 5$  and (ii) induces  $\alpha v \beta 3$ -mediated tyrosine phosphorylation of CAS and FAK in tumor cells.

Claim 13. (withdrawn) The homodimeric disintegrin of claim 12 having an amino acid sequence selected from the group consisting of:

- (a) amino acid numbers 419 to 483 of SEQ ID NO: 2;
- (b) an amino acid sequence at least 95% identical to (a) as determined by FASTA or BLAST using default opening and gap penalties and a default scoring matrix.

Claim 14. (withdrawn) A pharmaceutically acceptable composition comprising a pharmaceutically acceptable carrier and a homodimeric disintegrin according to claim 12.

Claim 15. (new) The method of claim 10, wherein said integrin is  $\alpha v \beta 3$  or  $\alpha v \beta 5$ .

Claim 16. (new) The method of claim 10, wherein the cells are exposed to contortrostatin.

## **II. RESPONSE TO RESTRICTION REQUIREMENT**

In response to the restriction requirement, Applicants elect Group I, claims 10 and 11 drawn to methods of inhibiting adhesion, with traverse.